Therapy update: An introduction to the pharmacology, safety, and efficacy of bispecific antibodies in relapsed or refractory multiple myeloma

Clicks: 10
ID: 320407
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #47 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose The treatment landscape for relapsed or refractory multiple myeloma (RRMM) has evolved significantly with the introduction of T cell–redirecting therapies. This review details key pharmacology, clinical efficacy, and safety information for bispecific antibodies (bsAbs) approved or under investigation for RRMM. Summary Multiple myeloma eventually relapses in nearly all patients, necessitating the continuous development of novel therapeutics. The 3 main targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor homolog 5 (FcRH5). Clinical trials have demonstrated robust single-agent efficacy in patient populations with difficult-to-treat RRMM, including in patients with penta-refractory disease. However, these therapies are associated with unique toxicities, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, as well as significant infection risks. Risk can be reduced through close monitoring, optimized premedication regimens, and step-up dosing strategies. Conclusion The remarkable efficacy of bsAbs in RRMM combined with a maturing understanding of their toxicity profiles is fundamentally reshaping the RRMM treatment landscape.
Reference Key
openalex_W7167887542 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dawud Ellayan
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag203
URL
https://doi.org/10.1093/ajhp/zxag203
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.